20 results about "Riboside" patented technology

The present invention relates to amino acid salts of nicotinic acid ribosides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+:wherein M1, R1, R2, and R3 are as described herein.

The invention discloses a preparation method of a nucleotide monomer, which comprises the following steps: taking methyl-D-ribofuranoside as an initial raw material, and finally realizing the synthesis of a compound monomer as shown in a formula P through the steps of selective protection, selective deprotection, C-C bond construction, acylating chlorination reaction, basic group introduction through glycosylation, deprotection, hydroboration oxidation and ring closing in sequence. By providing a brand new synthesis method, the reaction yield is improved, the cost of the whole synthesis molecule is reduced, the binding affinity of the prepared target nucleoside monomer serving as a reported drug applied to HCV resistance to RNA can be improved so as to further improve nuclease resistance, and the method has great significance for subsequent nucleic acid drug research.

The invention discloses a phenyl riboside compound as well as an extraction method and application thereof, and belongs to the technical field of agricultural herbicides. The compound is prepared from a plant endophytic fungus Neofusicoccum parvum LZUC-S1 through the steps of fermentation, ethyl acetate extraction and multiple chromatographic separation and purification. The compound is novel in structure and comprises seven phenyl riboside derivatives with different substituent changes. Experiments show that the compound disclosed by the invention has a remarkable inhibition effect on common field weeds such as chloris virgata, quinoa and purslane: under the concentration of 100 mg / L, the root length inhibition rates of the three weeds respectively reach 99.6%, 86.4% and 99.8%, and the bud length inhibition rates of the three weeds respectively reach 81.6%, 76.8% and 97.2%. In addition, the series of compounds have the characteristics of high efficiency, low toxicity and easiness in degradation, and can be applied to the field of green agriculture as a microbial herbicide.

The present invention relates to amino acid salts of nicotinic acid riboside of Formula I and compositions thereof, which are useful in the treatment of conditions and diseases associated with NAD+deficiency: wherein M 1 , R 1 , R 2 and R 3 as described herein.

To provide a method for treating a disease. [Solution] The present invention is NAD + This relates to the amino acid salt of nicotinic acid riboside of formula I, and its composition, which is useful for treating disorders and diseases associated with the deficiency of: TIFF2026063054000038.tif2048(here, M 1 , R 1 , R 2 , and R 3 (This is as described in the present specification.) Surprisingly, the present invention produces remarkable effects, as described in detail and demonstrated concretely in the present specification. These effects could not have been easily predicted by those skilled in the art from the prior art.

Methods for stabilizing or encapsulating at least one compound selected from the group consisting of nicotinamide riboside (NR), nicotinic acid riboside (NAR), nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), derivatives thereof, or salts thereof, are provided. Compositions including wax prills, stabilized, or encapsulated forms of at least one compound selected from the group consisting of nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, are also provided.

Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I:wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.

The present disclosure discloses compositions comprising maribavir, methods of providing the same, and compositions providing intermediates useful in providing maribavir. Maribavir is a benzimidazole riboside and is useful as an antiviral.

The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X-, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof, and novel crystalline forms thereof.

The present invention relates to amino acid salts of nicotinic acid nucleosides of Formula I and compositions thereof, which are useful in the treatment of conditions and diseases associated with NAD + deficiency: wherein M1, R1, R2 and R3 are as described herein. (I)

Compositions and methods of treatment for osteoarthritis and cartilage damage in a subject comprising administering to a subject in need thereof an effective amount of a nicotinamide-riboside (NR) and pterostilbene (PT) in a ratio of about 2:1.

The invention provides a compound growth regulator for promoting seedling emergence and ear strengthening of ratooning rice in the regeneration season and a preparation method and application thereof.The compound growth regulator is prepared from zeatin riboside, monopotassium phosphate, a surfactant and an alkaline solution, the zeatin riboside is dissolved in the alkaline solution, a proper amount of water is added to reach the target concentration, then the monopotassium phosphate is added to be dissolved, and the surfactant is added; adding a surfactant into the solution, and uniformly mixing; the compound growth regulator is sprayed once three days before ratooning rice is harvested in the first season and one day after the ratooning rice is harvested in the first season; the dosage of the compound growth regulator is 30-50 L / mu; the riboside zeatin and the monopotassium phosphate are used as the compound growth regulator of the ratooning rice, so that the ear number per unit area, the maturing rate and the yield in the ratooning season can be remarkably increased, and the effect is remarkably superior to that of singly applying the riboside zeatin or the monopotassium phosphate; the technical problems of insufficient field ear number and low yield of ratooning rice in the ratooning season can be solved, and the method has good application value.

The present invention relates to a method for determining the presence of lung cancer in a subject. The method comprises: (i) determining the level of one or more biomarkers in a sample from the subject; and (ii) comparing the level of said one or more biomarkers with the level of said one or more metabolites in a control sample to determine whether lung cancer is present in the subject. The biomarkers are selected from: 2-methoxyestrone 3-sulfate, testosterone glucuronide, androsterone glucuronide, 5a-dihydrotestosterone sulfate, corticrocin, octanoic acid, beta-citryl-L-glutamic acid, 2-hydroxymuconic semialdehyde, 5,6,11-dodecatriynoic acid, creatine riboside, 3-(Carboxymethyl)-3-hydroxypentanedioic acid, adenosine phosphosulfate, 7,8-dihydroneopterin 3'-phosphate, cis,cis,cis-10,13,16-Docosatrienoyl-CoA, inosine, N-(2,4-Dinitrophenyl)-2,4-dinitroaniline, prostaglandin M, pentadecenoic acid, PE(22:0 / P-18:0), carbamoyl phosphate, 2-hydroxy-3-oxohexanedioic acid, galactosylceramide (d18:1 / 22:0) and PE-NMe2(18:1(11Z) / 22:1(13Z)).

The disclosure relates to in vivo and ex vivo uses of dihydronicotinamide riboside (NRH), dihydronicotinic acid riboside (NARH) and reduced derivatives thereof to treat immune-related disorders (e.g., systemic inflammatory response syndrome and sepsis), kidney disorders (e.g., acute kidney injury and hepatorenal syndrome [HRS]), liver disorders (e.g., acute liver failure and HRS), hemolytic disorders (e.g., hemolysis and hemolytic anemia), and disorders and conditions associated with oxidative stress, damage or injury (e.g., methemoglobinemia and anemia). NRH, NARH and reduced derivatives thereof can be used in vivo or ex vivo alone or in combination with one or more additional therapeutic agents, such as an anti-inflammatory agent or / and an antioxidant.

The invention provides a synthetic method of acetyl bromo-uridine triphosphate. The method for preparing acetyl bromo-uridine triphosphate has the advantages of good process stability, high reaction efficiency, few side reactions and high purity of a target compound. The method disclosed by the invention is suitable for preparing acetyl bromo-uridine triphosphate in a large scale.

The invention discloses a preparation method of 3 '-propenyloxy furan ribonucleoside. The preparation method comprises the following steps: (1) protecting ribonucleoside by using tert-butyldimethylsilyl chloride; (2) carrying out complexing on the ribofuranoside protected by tert-butyldimethylsilyl chloride by using dioctyl tin oxide, so as to obtain a TBS-ribofuranoside-tin complex; (3) adding allyl methyl carbonate and tetrakis (triphenylphosphine) palladium into the TBS-ribonucleoside-tin complex for coupling, so as to obtain a coupling compound; 4, tetrabutylammonium fluoride is added into the coupling compound, a TBS protecting group is removed through a reaction, separation and purification are conducted, and the 3 '-propenyloxy ribofuranoside is obtained.According to the method, the 3'-propenyloxy ribofuranoside can be obtained only through one-time separation by adopting a three-step one-pot method, and industrial mass production is facilitated.

The present invention relates to phthalazinone derivatives, and includes pharmaceutical compositions and for the preparation of phthalazinone derivatives. More particularly, the present invention provides a pharmaceutical composition of phthalazinone derivatives for inhibiting the activity of the enzyme poly(ADP-riboside) polymerase.

Infant formula compositions and methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.

A method for determining the presence of lung cancer in a subject comprises: (i) determining the level of one or more biomarkers in a sample from the subject; and (ii) comparing the level of said one or more biomarkers with the level of said one or more metabolites in a control sample to determine whether lung cancer is present in the subject. The biomarkers are selected from: 2-methoxyestrone 3-sulfate, testosterone glucuronide, androsterone glucuronide, 5a-dihydrotestosterone sulfate, corticrocin, octanoic acid, beta-citryl-L-glutamic acid, 2-hydroxymuconic semialdehyde, 5,6,11-dodecatriynoic acid, creatine riboside, 3-(carboxymethyl)-3-hydroxypentanedioic acid, adenosine phosphosulfate, 7,8-dihydroneopterin 3’-phosphate, cis,cis,cis-10,13,16-docosatrienoyl-CoA, inosine, N- (2,4-dinitrophenyl)-2,4-dinitroaniline, prostaglandin M, pentadecenoic acid, PE(22:0 / P-18:0), carbamoyl phosphate, 2-hydroxy-3-oxohexanedioic acid, galactosylceramide (d18:1 / 22:0) and PE-NMe2(18:1(11Z) / 22:1(13Z)). The biomarkers may be detected using mass spectrometry, or by enzyme-linked immunosorbent assay (ELISA). Preferably, the sample is a urine sample.